This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buzaid, A. C. Articles by Atkins, M. Search for Related Content PubMed PubMed Citation Articles by Buzaid, A. C. Articles by Atkins, M.

Practical Guidelines for the Management of Biochemotherapy-related Toxicity in Melanoma

Oncology Center, Hospital Sirio-Libanes, Sao Paulo, SP 01308-050, Brazil [A. C. B.], and Cutaneous Oncology and Biologic Therapy Programs, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215-5400 [M. A.]

The combination of cisplatin-based chemotherapy with interleukin 2 (IL-2) and IFN-, referred to as biochemotherapy or chemoimmunotherapy, has shown promising antitumor activity in patients with metastatic melanoma. Phase II studies have reported overall response rates ranging from 40 to 60%, with durable complete remissions in 10% of the patients. Toxicity, however, is often severe and can be life-threatening if the healthcare team is not familiar with toxicity management. In this report, we briefly describe the clinical results of the most effective biochemotherapy regimens and provide a detailed description and management of the most common toxic effects, with emphasis on the concurrent biochemotherapy program initially developed at M. D. Anderson Cancer Center and currently being tested in a slightly modified version in two large-scale Intergroup Phase III trials.

This article has been cited by other articles:

				B. Taback, S. J. O'Day, P. D. Boasberg, S. Shu, P. Fournier, R. Elashoff, H.-J. Wang, and D. S. B. Hoon Circulating DNA Microsatellites: Molecular Determinants of Response to Biochemotherapy in Patients With Metastatic Melanoma J Natl Cancer Inst, January 21, 2004; 96(2): 152 - 156. [Abstract] [Full Text] [PDF]

				R. F. Kefford Adjuvant therapy of cutaneous melanoma: the interferon debate Ann. Onc., March 1, 2003; 14(3): 358 - 365. [Abstract] [Full Text] [PDF]